Japan has refined its standards for biological products by updating national release testing requirements to enhance product quality and consistency across key categories.
Japan Tightens Biological Product Release Testing
Importers must meet new national standards for quality, safety, and consistency.
What changed
Quality and safety standards updated through partial amendments to national release testing requirements.
Product consistency requirements enhanced to ensure uniformity and reliability in manufacturing.
Minimum Requirements framework amended to reinforce the regulatory compliance structure.
Who it affects
Importers of biological products must ensure products meet the updated national release testing protocols.
Manufacturers of monoclonal antibodies, vaccines, and therapeutic proteins must align production with the new consistency standards.
Compliance Answer: Japan’s Updated Standards for Biological Products and National Release Testing Requirements
Japan has refined its regulatory framework for biological products by amending the Minimum Requirements for Biological Products and the Public Notice on National Release Testing to enhance product quality, consistency, and public health safeguards. The updates introduce new standards for specific biological products and expand national release testing requirements. Below is a structured analysis of the key changes, authorities, and compliance obligations.
1. Overview of Regulatory Changes
The amendments focus on two primary areas:
- Minimum Requirements for Biological Products: Updates to manufacturing, quality, labeling, and storage standards for specific biological products1, 2.
- National Release Testing: Expansion of testing criteria, fees, and designated institutions for newly approved biological products1.
These changes are grounded in the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (PMD Act)1, 2.
2. Key Amendments and Requirements
A. Minimum Requirements for Biological Products
The following products are subject to updated or newly introduced standards:
| Product | Key Requirement | Authority | Citation |
|---|---|---|---|
| Freeze-dried Human Fibrinogen | Partial amendment to labeling requirements to align with revised package insert descriptions for proper use2. | MHLW* | 2 |
| Freeze-dried Live Attenuated Measles, Mumps, Rubella (MMR) Combined Vaccine | New standard added for manufacturing process, properties, quality, and storage1. | MHLW | 1 |
*MHLW: Ministry of Health, Labour and Welfare
B. National Release Testing
The Public Notice on National Release Testing is amended to include the following for the newly approved MMR vaccine:
| Aspect | Requirement | Authority | Citation |
|---|---|---|---|
| Testing Criterion | Newly approved MMR vaccine added as a subject for national release testing1. | MHLW | 1 |
| Fee | Fee for testing specified (exact amount not provided in sources)1. | MHLW | 1 |
| Quantity | Quantity of product required for testing specified (details not provided in sources)1. | MHLW | 1 |
| Institution | Designated institution(s) for conducting national release testing identified (details not provided)1. | MHLW | 1 |
3. Objectives and Rationale
The amendments aim to:
- Establish standardized manufacturing, quality, and storage requirements for biological products to ensure public health and sanitation1, 2.
- Expand national release testing to include high-priority biological products, ensuring consistent safety and efficacy before market distribution1.
4. Timeline and Implementation
| Action | Date | Citation |
|---|---|---|
| Proposed adoption | March 2026 (G/TBT/N/JPN/900) / May 2026 (G/TBT/N/JPN/905) | 1, 2 |
| Entry into force | March 2026 (G/TBT/N/JPN/900) / May 2026 (G/TBT/N/JPN/905) | 1, 2 |
| Final date for comments | 15 March 2026 (G/TBT/N/JPN/900) / 29 April 2026 (G/TBT/N/JPN/905) | 1, 2 |
5. Compliance Obligations
Manufacturers and distributors of biological products must:
- Align with updated standards: Ensure compliance with amended Minimum Requirements for Biological Products, particularly for Freeze-dried Human Fibrinogen and the MMR vaccine1, 2.
- Prepare for national release testing: For the MMR vaccine, comply with new testing criteria, fee structures, and designated institutions1.
- Monitor official publications: Amendments will be published in the Official Gazette (KAMPO) upon adoption1, 2.
6. Authority and Enforcement
- Primary Authority: Ministry of Health, Labour and Welfare (MHLW)1, 2.
- Enforcement: Compliance is mandatory under the PMD Act1, 2.
- Comment Submission: Stakeholders may submit feedback to the Japan Enquiry Point (Ministry of Foreign Affairs) until the specified deadlines1, 2.
Summary Answer
Japan has updated its Minimum Requirements for Biological Products and National Release Testing requirements to enhance the quality and consistency of biological products. Key changes include:
- Amendments to labeling standards for Freeze-dried Human Fibrinogen2.
- Introduction of new standards for the Freeze-dried Live Attenuated MMR Combined Vaccine, including its addition to national release testing1.
- Implementation timelines set for March 2026 (G/TBT/N/JPN/900) and May 2026 (G/TBT/N/JPN/905), with compliance mandatory under the PMD Act1, 2. Stakeholders must align with updated requirements and monitor official publications for final adoption.
Sources
- ↩ Partial amendment to the Minimum Requirements for Biological Products Partial amendment to the Public Notice on National Release Testing https://docs.wto.org/dol2fe/Pages/SS/directdoc.aspx?filename=Q:/G/TBTN26/JPN905.pdf&Open=True
- ↩ Partial amendment to the Minimum Requirements for Biological Products https://docs.wto.org/dol2fe/Pages/SS/directdoc.aspx?filename=Q:/G/TBTN26/JPN900.pdf&Open=True